Clinical and experimental aspects of tirbanibulin treatments

Area of Science:

• Dermatology
• Oncology
• Pharmacology

Background:

• Tirbanibulin is a topical medication approved for actinic keratosis (AK), a precancerous skin condition.
• It functions via dual mechanisms: microtubule inhibition and Src kinase inhibition.
• These mechanisms suggest potential applications in other epithelial cancers.

Purpose of the Study:

• To review tirbanibulin's applications beyond AK, specifically in squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).
• To evaluate tirbanibulin's safety, efficacy, side effects, and clinical experiences in various dermatological conditions.
• To explore its potential in anti-aging and skin lightening therapies.

Main Methods:

• Literature review of recent preclinical and clinical studies on tirbanibulin.
• Analysis of tirbanibulin's mechanisms of action, including microtubule and Src kinase inhibition.
• Evaluation of reported safety, efficacy, and side effect profiles.

Main Results:

• Tirbanibulin demonstrates potential therapeutic applications in squamous cell carcinoma and basal cell carcinoma.
• Evidence suggests tirbanibulin is a safe and effective treatment option for conditions beyond AK.
• Clinical experiences and safety data are being gathered for broader applications.

Conclusions:

• Tirbanibulin offers a promising treatment option for various epithelial cancers, extending beyond its initial indication for AK.
• Further research and clinical trials are warranted to fully establish its efficacy and safety in broader dermatological and oncological applications.
• Tirbanibulin's dual mechanism of action supports its versatile therapeutic potential in skin cancer and potentially in cosmetic dermatology.